Sanjiv Bhasin of IIFL says weakness in the domestic currency is likely to benefit pharma and not tech.“We have a target of Rs 750 on Sun Pharma and we remain extremely bullish. We think the weakness in the rupee should ideally be played out not by IT but by pharma,” he said.>Follow our full coverage on Indian rupee here